The Latest Cardiac and Vascular News
– Phase 3 RAPID trial of etripamil in patients with PSVT achieved primary efficacy endpoint; safety and tolerability data from repeat dose administration consistent with prior studies utilizing single-dose administration of etripamil – Analyses from etripamil Phase 3 PSVT studies featured during Late-Breaking session at AHA Scientific Sessions 2022 demonstrated significant reductions […]
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the third quarter ended September 30, 2022 and reviewed recent business highlights. “Silence’s third quarter was […]
NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2022. “In […]
Progress on Near-Term Growth Opportunities and Cost Savings LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) — LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced operational and financial results for the third quarter ended September 30, 2022. Q3 2022 revenue of $42.2 million compared to Q2 […]
SUNNYVALE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended September 30, 2022. “Our performance in the third quarter reflects broad-based U.S. TCAR strength […]
Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK and PASADENA, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) — Royalty […]
Contact: Beth Bales Senior Communications Manager, SVS (312) 334-2316 ROSEMONT, ILL. (Nov. 9, 2022) – The Society for Vascular Surgery (SVS) Foundation has been guided by the three long-term pillars of research and innovation, community vascular care and patient education, and disease prevention. Recently, the Foundation added a fourth pillar […]
SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2022. Recent Highlights Recognized revenue of $131.3 million […]
– Generated 38.8% growth in CGuard™ revenue year-over-year – – Continued enrollment in the C-Guardian US IDE trial, with 24 sites currently enrolling patients; on track to complete enrollment by approximately end of Q1 2023 – – Announced strategic partnership with NAMSA, a med tech contract research organization (CRO), to accelerate […]
MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2022. Q3 Results and Recent Highlights: Revenue of $2.1 million in the third quarter […]
